LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August1, 2017, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and six months ended June30, 2017.A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.
The information furnished to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
| 99.1* | Press release of Lantheus Holdings, Inc. dated August 1, 2017, entitled “Lantheus Holdings, Inc. Reports 2017 Second Quarter Financial Results; Exceeds Second Quarter and Raises Full-Year 2017 Guidance” |
| * | Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. |
Lantheus Holdings, Inc. ExhibitEX-99.1 2 d430462dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica,…To view the full exhibit click here
About LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.